Recently, Cereno Scientific announced positive topline results from the phase IIa trial of CS1 in pulmonary arterial hypertension. The results demonstrate that the candidate is safe, well tolerated, and has a positive impact on clinically relevant parameters. The phase IIa clinical trial data, together with preclinical information, are consistent with reversing pathological remodeling, which is in line with the development goals for CS1.
Read the article about Cereno Scientific at biostock.se:
https://www.biostock.se/en/2024/10/cerenos-phase-iia-results-looks-promising (https://www.biostock.se/en/2024/10/cerenos-phase-iia-results-positive-clear-path-forward)-clear-path-forward (https://www.biostock.se/en/2024/10/cerenos-phase-iia-results-positive-clear-path-forward)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/